Aval­on's lat­est biotech clos­es $58M round as it pur­sues treat­ments for au­toim­mune brain con­di­tions

Ar­ialys Ther­a­peu­tics an­nounced Tues­day that it tied the bow on a $58 mil­lion seed round to de­vel­op treat­ments specif­i­cal­ly for brain dis­or­ders caused by im­mune …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER